It was a pleasure to meet with Dr Jinhee Jo (Department of Pharmacy Practice and Translational Research, University of Houston, Houston, TX, USA) to discuss her study investigating the understanding of how C. Difficile is transmitted, and who it affects.
The abstract entitled: ‘Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
- What was the rationale for testing Clostridium difficile (C. diff) from both healthcare and non-healthcare sites?
- Could you give us an overview of your study, its sample size, and participating countries?
- What percentage of samples tested positive for C. diff and where was the bacteria found?
- How have these findings changed our understanding of C. diff infection?
- What can people do to prevent infection and reduce the spread of C. diff in the community?
Disclosures: Jinhee Jo has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
Share this Video
Related Videos In Bacterial Infections
Prosthetic joint infections – advances in diagnosis and treatment approaches: Robin Patel, ECCMID 2023
Prosthetic joint infections (PJI) are difficult to treat and require a multidisciplinary approach including surgical and therapeutic approaches to overcome infection. We were delighted to speak with Dr. Robin Patel (Mayo Clinic, Rochester, MN, USA) to learn more around the incidence, pathogenesis, and prognosis of PJI, the challenges in diagnosis and treatment of PJI and […]
Clostridioides difficile infection in paediatric patients: unmet needs and future challenges: Anne J. Gonzales-Luna, ECCMID 2023
Clostridioides difficile infection (CDI) is usually associated with older age; however, is becoming more prevalent in paediatric patients often in concurrence with comorbidities. There remains many unmet needs in the diagnosis and treatment of CDI in paediatric patients, with the mainstay of treatment being antibiotics. touchINFECTIOUS DISEASES spoke with Dr. Anne J. Gonzales-Luna (University of […]
Kayla Stover Hielscher, IDWeek 2022: Ceftriaxone as a treatment option for MSSA, ensuring optimum activity
Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use […]